In a filing, Alnylam Pharmaceuticals Inc revealed its Director BONNEY MICHAEL W unloaded Company’s shares for reported $3.12 million on May 15 ’25. In the deal valued at $277.71 per share,11,250 shares were sold. As a result of this transaction, BONNEY MICHAEL W now holds 16,804 shares worth roughly $4.9 million.
Then, BONNEY MICHAEL W bought 11,250 shares, generating $3,032,212 in total proceeds.
Before that, Reitan Colleen F bought 32 shares. Alnylam Pharmaceuticals Inc shares valued at $9,152 were divested by the Director at a price of $286.00 per share. As a result of the transaction, Reitan Colleen F now holds 32 shares, worth roughly $9339.52.
Redburn Atlantic initiated its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy in a research note published on March 31, 2025; the price target was $353. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in late March from “a Neutral” to “an Overweight”. Wolfe Research also remained covering ALNY and has decreased its forecast on November 12, 2024 with a “an Underperform” recommendation from previously “Peer perform” rating. Scotiabank started covering the stock on October 16, 2024. It rated ALNY as “a Sector outperform”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 2.30% to $291.86. Over the last five days, the stock has gained 8.02%. Alnylam Pharmaceuticals Inc shares have risen nearly 24.03% since the year began. Nevertheless, the stocks have risen 98.01% over the past one year.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-04-30, growing by 0.16 million shares to a total of 3.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 2.99 million shares. There was a rise of 5.07%, which implies that there is a positive sentiment for the stock.
